Meropenem 1000mg
Potent activity against gram-positive and gram-negative pathogenic bacteria. Greater efficacy than ceftazidime plus amikacin or tobramycin in patients with nosocomial pneumonia. Shows greater efficacy than ceftazidime or piperacillin/tazobactam in febrile neutropenia. Well tolerated and has good CNS and gastrointestinal tolerability.
Nosocomial pneumonia, Community-acquired pneumonia, Complicated intra-abdominal infections, Intra and post-partum infections, Complicated skin infections, Complicated urinary tract infections
As directed by the physician. Usually 500mg-1000mg every 8 hours IV infusion.
Diarrhea, nausea, vomiting, headache, rash, injection site reactions. Rarely seizures.
Use with caution in patients with CNS disorders. Monitor renal function in elderly patients.